Carlyle in its acquisition of bluebird bio, Inc.

On February 21, 2025, bluebird bio, Inc. (NASDAQ: BLUE), a biotechnology company that develops gene therapies for severe genetic disorders, announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP, pursuant to which bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird meets a specified net sales milestone, for a potential total value of up to $9.84 per share in cash.  In connection therewith, bluebird’s lenders agreed to leave their debt outstanding after consummation of the transaction on modified terms.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Carlyle.